The ability of immature neurons from chick lumbosacral sympathetic ganglia to proliferate in vitro was used to identify factors that affect neurogenesis. Under serum-free culture conditions, insulin-like growth factor I (IGF-I), IGF-II, or insulin caused an increase in the proportion of cells that incorporated [3H]thymidine. In addition, IGFs also stimulated neurite outgrowth from these immature sympathetic neurons. IGF-I and IGF-II mRNA was found to be expressed in E7 sympathetic ganglia during the period of neurogenesis. IGF-I was detectable in fibroblasts, whereas IGF-II mRNA was expressed by neurons, glia, and fibroblasts. Elimination of endogenous IGFs by neutralizing antibodies resulted in a reduction of neuron proliferation and neuron number, whereas elevation of IGF levels by treatment with IGF-I increased sympathetic neuron proliferation in vivo. These findings suggest an important role of IGFs for the development of sympathetic neurons and imply a general role of IGFs in the control of neurogenesis and neurite outgrowth.
Introduction
The peripheral nervous system is derived from precursors in the neural crest. After crest cell migration and aggregation to form primitive ganglia, a defined number of neurons is generated by proliferation and differentiation of neuron precursor cells. It is widely accepted that neuronal development, from early determination events to the final acquisition of specialized phenotypic traits, is influenced by environmental cues. With the exception of factors controlling neuron death (Snider, 1994) , the signals involved in these interactions between developing precursor cells and their environment are largely unknown. In particular, neurogenesis and the signals that control the proliferation of neuron progenitor cells are not understood at the molecular level in vertebrate systems. There is evidence from experimental embryology suggesting that neurogenesis in the CNS and PNS is subject to extrinsic control (Rohrer, 1990) . The persistent survival of neuron progenitors after neurogenesis in peripheral ganglia of chick embryos (Xue et al., 1985) suggests negative control mechanisms that prevent the proliferation of such cells during normal development. Similar precursor cells were shown to be present even in adult avian (Alvarez-Buylla et al., 1990) and mouse brain (Reynolds and Weiss, 1992) . Evidence for positive effects on neuron proliferation was obtained in the spinal cord after grafting notochord (Van Straaten et al., 1989) or embryonic gut (Rothman et al., 1987) in the vicinity of the spinal cord.
In culture, different growth factors have been shown to stimulate the incorporation of [3H]thymidine into neuron precursors derived from the CNS. Fibroblast growth factor (FGF) and epidermal growth factor (EGF) affected cell cultures of embryonic rat (Gensburger et al., 1987) and mouse brain (Drago et al., 1991) , retina (Anchan et al., 1991) , and cerebellum (Gao et al., 1991) . Insulin-like growth factor I (IGF-I) increased the proportion of thymidine-labeled neurons in cell cultures of embryonic rat telencephalon (Lenoir and Honegger, 1983) . However, the analysis of neurogenesis in these experimental systems is complicated by the fact that the proliferating cells are undifferentiated and have been identified and quantified only after their differentiation to neurons. Thus, an increase in the number of thymidine-labeled neurons may be due to increased survival of precursor cells and/or neurons, increased proliferation, or differentiation.
In contrast to other neuronal populations, proliferating cells that belong to the neuronal cell lineage can be unambigously identified in the developing sympathoadrenal system. Whereas in other parts of the nervous system proliferating neuron progenitors are undifferentiated, cells of the sympathoadrenergic cell lineage express differentiated, adrenergic properties during their proliferation phase (Rothman et al, 1978; Rohrer and Thoenen, 1987) . In addition to these adrenergic markers, neuron-specific characteristics are also expressed . Embryonic chick and rat sympathoadrenergic cells and postnatal rat adrenal chromaffin cells (Lillien and Claude, 1985; Stemple et al., 1988; Claude et al., 1988; DiCicco-Bloom and Black, 1988; Rohrer and Thoenen, 1987; Ernsberger et al., 1989b) were previously shown to proliferate in vitro. In cultures of rat sympathoadrenal cells, stimulation of [3H]thymidine incorporation was described for the neurotrophin nerve growth factor (NGF; Lillien and Claude, 1985; Stemple et al., 1988) and the growth factors aFGF, bFGF, EGF, IGF-I, and insulin (Claude et al., 1988; Stemple et al., 1988; DiCicco-Bloom and Black, 1988) .
Although these results clearly demonstrate that developing sympathoadrenal cells in culture respond to these factors, the significance of these findings for normal development remains unclear.
We have now used immature chick sympathetic neurons to identify factors that are able to stimulate neuron proliferation both in vitro and in vivo. IGF-I, IGF-II, and insulin were found to act as in vitro proliferation factors. We also observed a stimulation of [3H]thymidine incorporation into sympathetic neurons in vivo in response to IG F-I. A physiological role of IGFs in sympathoadrenal development is further evidenced by the finding that IGF-I and IGF-II mRNA is present in sympathetic ganglia during neurogenesis. IGF-I mRNA could be detected in ganglion fibroblasts; IGF-II mRNA was observed in all cell types present in the ganglion. The importance of endogenous IGFs for sympathetic neuron development was underscored by the ability of neutralizing anti-IGF-I antibodies to decrease neuron proliferation and neuron number in sympathetic ganglia.
Results

IGF-I, IGF-II, and Insulin Stimulate Sympathetic Neuron Proliferation
Immature chick sympathetic neurons from 7-day-old chick embryos proliferate in serum-supplemented media . Under these culture conditions, neuronal proliferation seems to be maximally stimulated, as the extent of [3H]thymidine incorporation could not be increased by the addition of growth factors (Ernsberger et al., 1989b) . Thus, to identify factors that affect sympathetic neuron proliferation, cells were maintained in a defined medium. Under these conditions virtually no thymidineincorporating cells could be detected, but all of the plated neurons (106% -+ 7%; n = 4) were alive after 3 days in culture. Thus, an increase in the proportion of [3H]thymidine-incorporating cells reflects increased proliferation rather than increased survival. In this way, it was possible to demonstrate that sympathetic neurons resume the incorporation of [3H]thymidine in the presence of IGF-I, IGF-II, and insulin ( Figure 1 ). The proliferation rate at saturating concentrations of these growth factors is similar to the extent of proliferation observed previously in cultures with serum-supplemented medium (Ernsberger et al., 1989b) . The concentration that promoted half-maximal DNA synthesis was 5 x 10 -9 M for human IGF-I (hlGF-I) and 2 x 10 -9 M for chick IGF-I (clGF-I; data not shown). Interestingly, hlGF-II was observed to be more active on sympathetic neurons (EDs9 of about 2 x 10 -9 M) than hlGF-I.
The action of IGFs is modulated by IGF binding proteins (IGFBPs), which have a higher affinity to IGFs than IGF receptors (Cohick and Clemmons, 1993) . To exclude the potential influence of IGFBPs on the determination of IGF potencies, a variant of IGF-I (tlGF-I) was tested that is not bound by IGFBPs. This truncated form of hlGF-I (tlGF-I), which differs from full-length IGF-I by the lack of the first three amino-terminal amino acids (Carlsson-Skwirut et al., 1989) , indeed displayed the highest biological activity (EDso of about 5 x 10 -l° M; Figure 1 ). Thus, this result suggests the presence of IGFBPs in these cultures that may interfere with IGF-I and IGF-II, but not with tlGF-I (Carlsson-Skwirut et al., 1989) . The ECso for insulininduced proliferation was about 4 x 10 -a M. Because insulin at high concentrations activates the IGF-I receptor (Sara and Hall, 1990) , it seems likely that the effect of insulin is mediated through the IGF-I receptor. The effects of IGFs and insulin on sympathetic neuron proliferation are not only reflected by a stimulation of thymidine incorporation, but also by an increase in cell number (data not shown) that is similar to the increase in sympathetic neuron number in the serum-supplemented medium (Ernsberger et al., 1989b) . As the sympathetic ganglion cell cultures consist of 95% neurons , it seems likely that IGFs and insulin act directly on sympathetic neurons. This assumption was confirmed using cultures devoid of nonneuronal cells. IGFs were found to stimulate proliferation in immunoselected, pure neuronal cultures (99.8% Q211-positive neurons) to the same extent as in unselected cultures (data not shown).
IGFs Stimulate Neurite Outgrowth
After the period of neuronal proliferation, sympathetic neurons start to innervate their peripheral targets, and it seemed of interest to investigate the effect of IGFs on initial neurite extension since a stimulatory effect of IGFs on neurite outgrowth has been described previously for postrnitotic sympathetic, sensory (Recio-Pinto et al., 1986) , and motor neurons (Caroni and Grandes, 1990) . The effect of IGFs on the neurite outgrowth of sympathetic neurons was first analyzed on laminin, the substrate we routinely use for the culture of immature PNS neuron cultures. Neurite outgrowth was stimulated by IGFs, but not by NGF ( Figure 2A ). As the stimulatory effect of IGFs on laminin was relatively small, we also investigated their effect on a substrate, fibronectin, which stimulates neurite outgrowth to a much lesser extent than laminin (Ernsberger et al., 1989a) . On fibronectin substrates, only a small proportion of the cells produced long neurites within the first day in culture. However, IGF-I and IGF-II elicited a large increase in the proportion of neurite-bearing cells ( Figure 2B ). The IGF-induced increase in the proportion of cells with long neurites may be explained by a selective proliferation of cells that are able to grow long processes, rather than by a direct effect of IGFs on neurite outgrowth. The former possibility was excluded, however, as the prop6rtio n of [3H]thymidine-labeled neurons with long neurites turned out not to be significantly different (59% _+ 4% and 62% _ 4% for IGF-I and IGF-II, respectively) from the proportion of labeled cells with short neurites (61% -+ 6% and69e/o _ 6% for lGF-I and IGF-II, respectively). Thus, both on laminin and on fibronectin substrates, the IGFs stimulate the formation of neurites in immature sympathetic neurons.
Expression of IGF-I and IGF-II mRNA in Sympathetic Ganglia
Both IGF-I and IGF-II display distinct and different expression patterns during embryonic development, suggesting a local autocrine or paracrine role in these tissues (Kikuchi et al., 1991; Rotwein et al., 1988; Bondy et al., 1990) . In Before RNA extraction, a defined amount ef exogenous IGF-I or IGF-II RNA standard (see Experimental Procedures) was added to the tissues. RNA was extracted, reverse transcribed, and amplified by PCR (27 cycles) using primers specific for either IGF-I or IGF-II. The products were separated by gel electrophoresis, blotted, and visualized by hybridization with internal IGF-I-or IGF-II-specific oligonucleotide probes. In parallel, different concentrations of standard mRNAs were also amplified.
(A) IGF-I determination; Southern blot of amplified products !rom E7 sympathetic ganglia, E7 liver, and control without RNA and different concentrations of standard RNA (72, 36, 18, 9, 4.5, 2.3 , and 1.1 fg).
(B) IGF-II determination; same as in (A), but with IGF-II standards (300, 150, 75, 37.5, 18.75, 9.3, 4.7, 2. To detect and quantitate the amount of IGF-I and IGF-II mRNA in the developing chick sympathetic ganglia, a sensitive PCR-based detection method was used (see Experimental Procedures). We could detect IGF-I and IGF-II rnRNA in E7 chick sympathetic ganglia, but only IGF-II mRNA was observed in the liver at that stage of development ( Figures 3A and 3B ). IGF-II mRNA is expressed in E7 sympathetic ganglia at higher levels than IGF-I, and as expected from previous studies in mammalian embryos (Sara and Hall, 1990) , large amounts of IGF-II mRNA were found in E7 liver (Table 1) .
To identify the cellular source of IGFs in E7 sympathetic ganglia, the different cell types present were immunoselected using cell type-specific antibodies that recognize cell surface antigens . The ganglia contain at that stage of development a very high proportion of neurons (95o) that can be identified by the antibody Q211, as well as about 2% glial cells, recognized by the monoclonal antibody (MAb) 04, and about 3% fibroblasts . The fibroblast population, defined by the absence of glial and neuronal markers and by the expression of fibronectin (Rohrer, 1985) , is expected to include endothelial cells and endoneurial fibroblasts. Immunoselection for Q211 or 04 antigenexpressing cells resulted in pure neuronal and glial cell populations. Fibroblasts were selected by elimination of Q211-and O4-positive cells using complement-mediated cell lysis . Interestingly, IGF-I mRNA was detectable only in fibroblasts ( Figure 3C ). The neuronal and glial cells were negative for IGF-I mRNA even after 40 PCR cycles. In contrast, IGF-II mRNA was found in neurons and fibroblasts ( Figure 3D ) and, at very low levels, in glial cells (detectable after 40 PCR cycles). The levels of IGF-II mRNA in dissociated cells correspond to the amount of IGF-II found in intact ganglia (Table 1) , as neurons account for 95% of the ganglion cells. In contrast, the amount of IGF-I mRNA in fibroblasts was much lower than expected from the observation that fibroblast IGF-I mRNA accounts for all the IGF-I mRNA in the ganglion. This discrepancy may be explained by a preferential loss of fibroblasts during the dissociation of the ganglia or by degradation of IGF-I mRNA. These results indicate that E7 sympathetic ganglion cells may have access to IGFs produced locally in the ganglion, and that IGF-II, owing to the higher mRNA expression level and a possible autocrine action, may be more relevant for sympathetic neuron proliferation than IGF-I. In addition, the possibility has to be considered that IGF-II may also reach the ganglion as a systemic endocrine factor derived from the liver.
To investigate whether the expression of IG Fs correlates with the extent of proliferation, we also analyzed a later stage of development (E12), when neuron proliferation in sympathetic ganglia is decreased (Rothman et al., 1978) . We observed that the levels of IGF-I mRNA remained constant during this period (15 _+ 1.8 fg of IGF-I mRNA per microgram of RNA at E12), and the IGF-II mRNA levels increased about 5-fold to 161 + 17 fg of IGF-II mRNA per microgram of RNA at E12. The lack of correlation between 
IGF-I Stimulates Sympathetic Neuron Proliferation In Vivo
The effects of IGF-I observed in vitro suggest a function of IGF-t for two important steps of normal development of sympathetic neurons, proliferation and neurite outgrowth.
To support the proposed action of IGFs, we studied the effects of IGF-I on sympathetic neuron proliferation in vivo. The avian embryo is well suited to analyze the effects of biologically active substances during development, since factors applied to the chorioallantoic membrane are delivered to the embryo. Quail embryos were used for the first series of experiments, as it seemed likely that less factor would be required than for chick embryos, owing to the considerably smaller size of quail eggs. IGF-I was applied on days 4, 5, and 6, and thymidine incorporation was analyzed at day 6 (Table 2 ). In a second series, tlGF-I was applied onto the chorioallantoic membrane of chick embryos at days 5, 6, and 7, and thymidine incorporation was analyzed later on day 7. Both experiments indicate a significant increase in sympathetic neuron proliferation upon addition of IGF-I (Table 2) . Obviously, the extent of stimulation by exogenous application of factors depends on the proliferation status of the cells, controlled by endogenous growth factors. The present result thus indicates that sympathetic neuron proliferation is not maximally stimulated in vivo and can be modulated by extrinsic control both in vitro and in vivo.
Anti-IGF-I Antibodies Diminish Proliferation and Neuron Number in Sympathetic Ganglia
After demonstrating effects of IGFs on sympatheticneuron proliferation in vitro and in vivo, we tried to support the proposed role of IGFs for sympathetic neuron develop- Control 55 ± 4 (n = 4)(1000/0) Anti-IGF-I 42 ± 4 a (n = 4)(76%)
Quail embryos were treated with antibody-producing hybridoma cells, and the proportion of thymidine-labeled neurons was determined at E6 as described in Experimental Procedures, p < .005 ment by interfering with their action in vivo, using the neutralizing MAb sin1.2 raised against hlGF-I. The ability of this antibody to neutralize the biological effects of different IGFs was first assayed in vitro. The antibody crossreacts with hIGF-I, clGF-I, and, to a lesser extent, hlGF-II. To obtain a 10-fold reduction of the proliferative effect of 50 ng/ml clGF-I or hlGF-I (7 x 10 -9 M), an antibody concentration of 5 i~g/ml is needed. The neutralization of 50 ng/ml hlGF-II required considerably higher antibody concentrations (20 ~g/ml). The degree of crossreactivity of the antibody to clGF-II is not known. As described previously (Russell et al., 1984) , the antibody did not antagonize the effect of insulin. To obtain sufficiently high antibody titers in the embryo, the antibody-producing hybridoma cells were applied onto the chorioallantoic membrane of 3-to 4-day-old quail embryos . The antibody concentration was determined in brain homogenates and amounted to 5-12 I~g/g tissue for both control and anti-IGF-I antibodies.
The effect of antibody treatment on sympathetic ganglion proliferation was monitored by in vivo [3H]thymidine labeling at E6. We observed a 24% reduction in the proportion of [3H]thymidine-labeled sympathetic neurons in anti-IGF-I-treated embryos compared with controls (Table 3) . The same reduction (24% _+ 8%; p < .025) was observed when anti-IGF-I-treated embryos and anti-glycine-receptor-treated embryos were compared.
Antibody treatment resulted also in a reduction in the number of sympathetic neurons. Neuron numbers were determined in sections of E9 lumbosacral sympathetic ganglia (L3/4) from quail embryos that were grown without antibodies, with an unrelated antibody or with anti-IGF-I antibody sin1.2. The neuron number was found to be reduced by about 20% compared with both controls (Table  4) . Thus, elimination of endogenous IGFs by neutralizing antibodies reduces sympathetic neuron proliferation and neuron number. These findings clearly demonstrate that IGFs are important for sympathetic neuron development.
Discussion
Growth factors, and in particular IGFs, have been implicated in the control of neurogenesis and neuron differentiation (Rohrer, 1990) . The present study investigated the effects of IGF-I and IGF-II on chick sympathetic neuron proliferation and neurite outgrowth. We demonstrate that proliferation of chick sympathetic neurons is stimulated 
Quail embryos were treated with hybridoma cells as described in Experimental Procedures, and neuron number was determined in sections from E9 quail embryos (lumbar segment L3/4). Data are expressed as mean -SEM (19, 15, and 5 embryos were analyzed as indicated).
p < .05.
by IGFs both in vitro and in vivo, and that IGF-I and IGF-II mRNA is expressed in the ganglion at the time of neuronal proliferation. We also show a neurite-promoting effect of IGFs for sympathetic neurons at an early stage of development, when very few cells respond to NGF. A function of endogenous IG Fs for normal sympathetic neuron development was demonstrated by the application of anti-IGF-I antibodies that resulted in a reduction of proliferation and neuron number in sympathetic ganglia. Chick sympathetic neurons were shown previously to survive and proliferate in vitro in serum-containing medium Ernsberger et al., 1989b) . We now demonstrate that under serum-free conditions all chick sympathetic neurons survive for a culture period of 3 days, but are arrested in their proliferation. These conditions were used to test growth factors for their ability to stimulate sympathetic neuron proliferation. We found that neuronal proliferation, reflected by an increased proportion of [3H]thymidine-labeled neurons and by an increase in neuron number, was resumed after addition of IGFs or insulin, and we provided evidence that these effects are due to a direct action of IGFs and insulin on sympathetic neurons.
To stimulate neuronal proliferation, much higher concentrations of insulin were needed as compared with IGF-I and IGF-II. IGF-I and IGF-II activate the IGF-I receptor at nanomolar concentrations. At about 100-fold higher concentrations, they are also known to bind to and elicit biological effects at the insulin receptor (Sara and Hall, 1990 ). Conversely, insulin is able to activate the heterologous IGF-I receptor at high concentrations. The present data thus suggest that the effects of insulin are mediated through the IGF-I receptor and that the IGF-I receptor and its ligands are involved in the control of neuronal proliferation. It should be noted, however, that hlGF-II, which is 10-fold less potent than hlGF-I on cells expressing hlGF-I receptors (Germain-Lee et al., 1992) , was more active than hlGF-I on chick sympathetic neurons. This may be due either to previously described untypical properties of the avian IGF-I receptor (Duclos and Goddard, 1990) or to the presence of another receptor (XR) that has been implicated in the action of IGF-II (Baker et al., 1993 ). An involvement of the mannose 6-phosphate receptor/IGF-II recep-tor is excluded, as the avian receptor lacks the IGF-II binding site (Clairmont and Czech, 1989) . It was observed previously that truncated IGF-I, which is an IGF-I variant lacking the first three amino acids at the amino terminal, was more active than full-length IGF-I (Carlsson-Skwirut et al., 1989) . IGF-I and tlGF-I do not differ significantly in their affinity to the IGF-I receptor (Ballard et al., 1986; Carlsson-Skwirut et al., 1989) . The difference in their biological activity is due to a difference in interaction with IGFBPs. Whereas IGFBPs bind to normal IGF-I and IGF-II and prevent their interaction with the receptor, they are much less potent inhibiting the action of tlGF-I (CarlssonSkwirut et al., 1989) . IGFBPs were first discovered in serum and were considered as the carrier proteins for endocrine IGF-I produced in the liver, but were later found to be produced in many tissues (Cohick and Clemmons, 1993) . Our finding that tlGF-I is more active than hlGF-I or IGF-II suggests that IG FBP(s) is also present in sym pathetic neuron cultures and, by partly neutralizing IGF-I and IGF-II, may account for the lower specific activity of these agents compared with tlGF-I.
A complex picture is obtained when studies on effects of different growth factors on neuronal precursor cells from various parts of the nervous system are compared (Gao et al., 1991; DiCicco-Bloom et al., 1990; Anchan et al., 1991; Lillien and Cepko, 1992; Drago et al., 1991) . The results suggest that proliferation of neuronal precursor cells in different parts of the nervous system may bedependent on the presence of different factors or on a different combination of factors. This would be analogous to the situation in the hematopoietic system, where progenitor cells that are committed to different cell lineages depend on different growth factors (Metcalf, 1991 ). An additional explanation for different growth factor responses observed for different precursor cell cultures is that cells may change their growth factor requirements during maturation (Metcatf, 1991) . There is indeed strong evidence that neurons and glial cells change their requirements for growth factors (Lillien and Cepko, 1992; Barres et al., 1993) and survival factors (DiCicco-Bloom et al., 1993; Birren et al., 1993) during development. On the other hand, it is very striking that, whenever investigated, effects of IGFs on neuron proliferation have been observed. This suggests that IGFs may be active in many neuronal lineages and interact with different factors, depending on the cell lineage. In cultures of neuroepithelial cells, it was observed that the proliferation effect of FGF is dependent on the expression and function of IGF-I (Drago et al., 1991) . A similar observation was made for oligodendrocyte precursor cells, for which a proliferation effect of neurotrophin-3 was found to be dependent on IGF-I (Barres et al., 1993 (Barres et al., , 1994 . There is, however, also evidence for independent action of two growth factors. Neurotrophin-3 was shown to act as a survival factor for rat sympathetic neurons, whereas IGFs or FGF seem to be responsible for cell proliferation (DiCicco-Bloom et al., 1993; Birren et al., 1993) .
In the nervous system, IGFs are known to affect another important step in neuron development, the production of neurites. IGF-II and insulin have been shown to stimulate neurite outgrowth from chick sympathetic (E12) and sensory neurons (El0; Recio-Pinto et al., 1986) . In E12 chick embryos, the majority of sympathetic neurons have innervated their peripheral target (Kirby et al,. 1978 ). Neurite outgrowth from postmitotic sympathetic neurons observed in these experiments thus represents the regeneration of axons that were lesioned during the dissection and dissociation of the ganglia. In contrast, the ganglion cells at E7 are proliferating, immature neurons, and the neudtes produced in vitro represent initial neurite outgrowth rather than regeneration. There is general agreement that the initial neurite outgrowth of sympathetic and sensory neurons occurs independently of NGF both in vitro and in vivo, whereas neurite outgrowth from mature neurons is strongly stimulated by NGF (Coughlin and Collins, 1985; Davies et al., 1987; Ernsberger and Rohrer, 1988; Ernsberger et al., 1989a) . As factors involved in the initial, NGFindependent outgrowth of neurites to their target are unknown, it was of interest to investigate whether IGFs are also acting at this early stage. We found that initial neurite outgrowth is indeed stimulated by IGFs on both laminin and fibronectin. These in vitro observations suggest that initial outgrowth may be controlled by the presence of outgrowth-promoting molecules of the extracellular matrix (Ernsberger et al., 1989a) and of soluble growth factors. Thus, it seems that IGFs are able to stimulate neurite production at all stages of development, from the initial neurite outgrowth to the sprouting (Caroni and Grandes, 1990) and regeneration (Kanje et al., 1989; Near et al., 1993; Glazner et al., 1993 ) of mature axons.
The effects of IGFs on sympathetic neuron proliferation and neurite outgrowth observed in vitro lead to the question of whether IGFs are available to developing sympathoadrenal cells during neurogenesis. Both IGF-I and IG F-II are expressed during mammalian fetal development in many tissues (Sara and Hall, 1990; Cohick and Clemmons, 1993) , but the expression of IGF-I and IGF-II mRNA during early chick development is only poorly documented (Serrano et al., 1990; Kikuchi et al., 1991) . Using a sensitive PCR-based detection method, we now demonstrate that both IGF-I and IGF-II mRNAs are expressed in E7 sympathetic ganglia. The level of IGF-II mRNA expression is higher than that of IGF-I, and a major site of IGF-II expression is the embryonic liver. These findings suggest that IGF-I and/or IGF-II, either produced in the ganglion or provided as endocrine growth factor from the liver, are available during neurogenesis in sympathetic ganglia. Using immunoselection procedures to analyze IGF-I and IGF-II mRNA levels in defined ganglion cell populations, we observed that IGF-I mRNA is expressed by ganglion fibroblasts, whereas IGF-II is expressed by neurons and fibroblasts and, at low levels, by glial cells. The cellular localization of IGF-I and IGF-II mRNA is compatible with both paracrine and autocrine modes of action of IGFs on sympathetic neurons. In contrast to our results on chick sympathetic neurons, in situ hybridization studies on developing rat PNS could not detect a signal for IGF-I in sympathetic ganglia (Bondy et al., 1990) , and IGF-II mRNA was detected in PNS ganglia only in endothelial cells lining blood vessels (Bondy et al., 1990; Ayer-Le Lievre et al., 1991) .
The difference observed may be due to a species difference, but a more likely explanation is the different sensitivity of the methods used. Although the early expression of IGF-I and IGF-II in developing peripheral ganglia is in agreement with the proposed role of these growth factors in the control of neurogenesis, the expression of IGFs increases rather than decreases in the ganglion at the end of neurogenesis. This suggests a role for IGFs in later aspects of development (e.g., cell survival or neurite outgrowth). In support of such a role, it should be mentioned that during regeneration, a process that often recapitulates developmental schemes, IGF-I and IGF-II mRNA expression is up-regulated in peripheral nerves (Glazner et al., 1993, Soc. Neurosci., abstract) .
Evidence for a role of IGFs in neuron development has also been obtained in developing CNS by the analysis of the expression of IGF-I receptor and IGF-I mRNA. It was found that IGF-I receptor is expressed in all proliferative zones (Bondy et al., 1992) , whereas IG F-I m RNA, analyzed by in situ hybridization, is undetectable in these regions (Bondy et al., 1992; Ayer-Le Lievre et al., 1991) . These results argue against an autocrine effect of IGF-I but do not exclude paracrine effects of IGF-I produced by earlier differentiated neurons . In addition, as sensitive RNA blot analysis indicates the presence of IGF-I mRNA in El0 mouse brain neuroepithelium (Drago et al., 1991) and E14 rat brain (Rotwein et al., 1987) , one may speculate that IGF-I is produced in proliferation zones at low levels that remain undetected by in situ hybridization. At: later stages, IGF-I mRNA was detected in early differentiating neurons (Bondy, 1991) . This result suggests that IGF-I may play a role in neurite growth or synaptogenesis in the CNS.
After establishing IGF mRNA expression during the period of neurogenesis, the role of IGF-I in sympathetic neuron proliferation was verified by the analysis of its in vivo action. Since IGF-I application also resulted in an increased number of thymidine-incorporating neurons in vivo, we conclude that the effects observed in vitro are of physiological relevance. It should be pointed out that the degree of stimulation obtainable in vivo by the addition of exogenous factors depends on the background levels of endogenous stimulation. The observed in vivo effect of IGF-I thus demonstrates that sympathetic neuron proliferation is not maximally stimulated in vivo.
The importance of endogenous IGFs for sympathetic neuron development was further demonstrated by the application of neutralizing anti-IGF-I antibodies. We could show that both sympathetic neuron proliferation and neuron number were reduced in embryos treated with anti-IGF-I antibodies. The extent of the antibody's effect on thymidine incorporation was similar to the effect on neuron number. Thus, the most parsimonious interpretation of the results would be that the reduced neuron number would be the result of a decrease in proliferation. The number of sympathetic neurons in E9 ganglia is, however, determined both by proliferation and by selective, neurotrophincontrolled survival. A reduced neuron production may enable a larger proportion of the neurons generated to survive in response to the limited amounts of neurotrophins. In addition, neurite outgrowth-promoting effects of IGFs are considered to be important to guarantee uptake of neurotrophins and subsequent neuronal survival. Thus, the relative contribution of effects of anti-IGF-I on neuron proliferation or survival remain to be determined.
The limited effect of the antibody treatment could be due either to the fact that only subpopulations are responsive, to up-regulation of IGF-I production upon antibody treatment, to redundant control by other growth factors, or to the limited extent of IGF elimination. The last possibility seems not unlikely, as we observed a reduced crossreactiv'ty between the antibody and IGF-II. The antibodies neutralize the in vitro effects of recombinant hlGF-I and clGF-I with high efficiency, but higher concentrations are required to prevent the action of hlGF-II. This raises the possibility that mature clGF-II, which is about 62% homologous to clGF-I (Taylor and Brickell, personal communication), may be recognized to an even lesser degree by the antibody. Further work will be needed to determine the relative importance of IGF-I and IGF-II.
In conclusion, there is considerable evidence for effects of IGFs on sympathoadrenal cells throughout development. With respect to proliferation, we now have demonstrated that the cells respond in vivo in a similar way as in vitro. We also provided evidence indicating that endogenous IGFs are involved in normal development of sympathetic neurons. It is known that the final number of neurons generated is not due to a depletion of neuron precursors at the end of neurogenesis (Xue et al., 1985; Reynolds and Weiss, 1992) . Rather, the cessation of neurogenesis may be due to reduced levels of growth factors, to reduced responsiveness to growth factors, or to negative feedback control by the newly generated neurons. As IGF mRNA production in sympathetic ganglia increases rather than decreases at the end of neurogenesis, a reduction in the levels of IGFs cannot account for the cessation of proliferation. Our data suggest that IGFs are necessary for proliferation and play a permissive rather than an instructive role. Although the mechanisms that determine the number of neurons in different ganglia of one species, or different neuron numbers in ganglia of different species (Purves, 1988) , are still far from being well understood, our data strongly suggest that IGFs are involved in the control of neurogenesis.
Experimental Procedures
Materials
Recombinant hlGF-I, hiGF-II, and tlGF-I, which is commercially available as brain IGF-I, were purchased from Boehringer Mannheim (Mannheim, Germany). Recombinant clGF-I was from GRO PEP (Adelaide, Australia). Insulin (bovine, cell culture-tested), Putrescine, transferrin, progesteron, selenium, heparin, and bovine serum albumin (BSA; A4161 or A7906) were from Sigma (Deisenhofen, Germany). NGF was prepared as described previously . The MAb Q211 was a generous gift from S. Henke-Fahle, Augenklinik der Universit&t TL~bingen, T~Jbingen, Germany. The MAb 04 was diluted from a concentrated hybridoma supernatant. The hybridoma cells producing anti-IGF-I antibodies (clone sin1.2; Russell et al., 1984) were obtained from UBI (Lake Placid, New York). The hybridoma (sm t.2) was generated by immunizing mice with hlGF-I. The hybridoma cells producing anti-glycine receptor (mab2) were obtained from Dr. A. Kirsch, Dept. Neurochernistry, MPI fLir Hirnforschung, Frankfurt, Germany.
Cell Culture
Lumbosacral sym pathetic chain ganglia were dissected from 7-day-old (E7) chick embryos, and neurons were prepared and cultured as described (Ernsberger et al., 1989a (Ernsberger et al., , 1989b . For serum-free cultures, we used Ham's F14 medium supplemented with putrescine (100 ~M), transferrin (5 ~.g/ml), progesteron (20 nM), and selenium (30 nM). Cell counts were obtained by examining phase-bright cells in randomly selected fields of the culture dish. Approximately 5% of the total surface of the dish was examined, and triplicates (three dishes) were counted for each parameter in each experiment. Effects of IGFs on neurite formation were assayed after a culture period of 3 or 24 hr in dishes coated with laminin or fibronectin, respectively, by determining the proportion of neurons with long processes (>/4 cell diameters) in cultures stained with the neuron-specific cell surface antibody Q211 as described previously (Ernsberger and Rohrer, 1988; Ernsberger et al., 1989a) . Data were analyzed for significant difference between controls and IGF-treated embryos using Student's t test with Bonferroni correction for multiple t tests. In some neurite growth experiments on fibronectin, [3H]thymidine was added at the time of plating, and after 24 hr the cells were stained with MAb Q211, processed for autoradiography, and analyzed for the proportion of neurons with long or short processes that were [3H]thymidine-labeled.
Pure neuronal or glial cells were prepared by irnmunoselection ("panning") using the cell type-specific MAbs Q211 and 04 (Rohrer et al., 1985; Rohrer and Thoenen, 1987) . Petridishes (100 mrn diameter; Greiner) were coated overnight with 10 rnl of 50 mM Tris-HCI buffer (pH 9.5) containing 5 ~g/ml rabbit anti-mouse IgM antibodies (Jackson Laboratories). After washing of the dishes with PBS (3 x), they were coated with 5 rnl of HEPES-buffered F14 medium containing MAb Q211 or 04 and 1 mg/ml BSA for 1 hr at room temperature. After washing of the dishes (3 x), about 1 x 10 ~ freshly dissociated cells from E7 sympathetic ganglia were added to the dishes for 45 min in the same medium. Nonattached cells were removed by washing with PBS (3 x). Attached cells were harvested by trypsinization and collected by centrifugation. Aliquots of the cells were replated and analyzed after 1 day in culture for the proportion of fibroblasts (Q211-and O4-negative), glial cells (O4-positive), and neurons (Q211-positive). The panning procedure resulted in pure neuronal populations (99.8% ± 0.20/0 Q221-positive [n = 3]) and populations strongly enriched for glial cells (960/0 ± 1.7% O4-positive [n = 3]). The selection for fibroblasts using complement-mediated cell lysis of Q211-and 04-positive cells resulted in populations virtually devoid of neurons and glial cells (99.7% ± 0.2% of the cells lacking both Q211 and 04 antigens; n = 3).
Sympathetic neuron proliferation was analyzed in vitro by adding methyl-[3H]thymidine (40-60 Ci/mmol; 1 p.Ci/rnl; Amersham, Braunschweig, Germany ) after 1 day in culture for 18-24 h r and processing for autoradiography as described previously (Ernsberger etal., 1989b; Rohrer and Thoenen, 1987) . The proportion of [3H]thymidine-labeled neurons was determined by analyzing 300 neurons per dish. Triplicates were counted for each data point.
Analysis of In Vivo Effects of IGF-I
Quail and chick eggs were incubated, and a window was made in the shell overlying the vascularized chorioallantoic membrane (CAM) on E3 (quail) or E4 (chick). hlGF-I was dissolved in PBS/glucose (4 mg/ ml), and 25 ~1 of this solution (containing 0.1 ~g of hlGF-I) was applied daily to the CAM. Control embryos were treated with PBS/glucose. Quail embryos were treated at days 4 and 5, in one case at days 5 and 6. Chick embryos were treated at days 5, 6, and 7. At E6 (quail) or E7 (chick), 20 ~Ci of [3H]thymidine was applied in a volume of 50 I~1 of PBS onto the CAM. After a 3 hr thymidine pulse, the ganglia were dissected, dissociated to single cells, and plated onto polyornithine/ laminin-coated dishes. Ganglia from 5-8 embryos were pooled for each experiment. Cells were allowed to attach to the culture dish for 3 hr, stained with MAb Q211, and processed for autoradiography. The proportion of cells that were both Q211-positive and [3H]thymidinelabeled was determined. Data were analyzed for significant difference between controls and IGF-I-treated embryos using Student's t test.
Antibody Treatment
The treatment of embryos with anti-IGF-I antibodies involves the growth of hybridoma cells in the egg as decribed previously . At E3 or E4, 2 x 106 hybridoma cells secreting anti-IGF-I antibodies (clone sm 1.2; Russell et al., 1984) or hybridoma cells secreting anti-glycine receptor antibodies (clone mab2; Pfeiffer et al., 1984) were applied onto the the CAM in 50 I~1 of PBS (pH 7.3). Experiments that were analyzed for neuron number received hybridoma cells at E3. After this morphological analysis was terminated, we observed that somewhat higher antibody titers are obtained at E7 when the hybridoma cells are applied at E4 rather than at E3; these conditions were used to investigate the effects of anti-IGF-I antibodies on sympathetic neuron proliferation.
Determination of Mouse Antibody Levels in Quail Tissues
The levels of anti-IGF-I antibody were determined in brain tissue using an enzyme imrnunoassay (enzyme-linked irnmunosorbent assay [ELISA]) for IGF-I. The brains were carefully dissected (without meninges), washed, and homogenized in 80 mM NaCI, 5 mM phosphate buffer (pH 7.4), supplemented with protease inhibitors phenylmethylsulfonyl fluoride (0.1 mM), leupeptin (0.1 M), benzamidin (1 mM), and aprotinin (20 KIU/ml). The soluble fraction was obtained by centrifugation. clGF-I was bound to 96-well plates, and supernatants of the tissue samples, diluted in PBS/0.1% Tween-20, were added to the plate. Bound anti-IGF-I antibody was detected using horseradish peroxidase-coupled anti-mouse irnrnunoglobulin and ABTS as substrate (Amersharn). A standard curve was constructed using known quantities of purified anti-IGF-I antibody (UBI). This assay measures the levels of biologically active antibodies that are able to interact with clGF-I. Alternatively, the levels of anti-IGF-I antibody and anti-glycine receptor antibody were determined by a two-site ELISA using affinitypurified anti-mouse IgG antibodies to coat the 96-well dishes. The levels of anti-IGF-I antibodies detected by both procedures were virtually identical.
Analysis of In Vivo Effects Of Anti-IGF-I Antibody
For the analysis of neuronal proliferation, quail embryos were treated with hybridoma cells or PBS, and then 20 p.Ci of [3H]thymidine was applied to the CAM. After about 8 hr, the ganglia were dissected, dissociated to single cells, and plated on polyornithine/laminin-coated dishes. After plating, the proportion of [3H]thymidine-labeled cells was determined as previously described . Ganglia from different embryos were analyzed separately. Statistical significance was determined using unpaired Student's t test.
For histological analysis of sympathetic neuron number, embryos were fixed at E9 in Bouin's fixative, embedded in paraffin, and sectioned at 6 p_m. Sections were stained either with hematoxylin and eosin or with thionin. Neurons were counted in every fifth section through L3 or L4 sympathetic ganglion. As described previously (Oppenheim et al., 1989) , only large to moderate sized cells containing substantial cytoplasm and a distinct nucleus and nucleolus were included in the cell counts. The size of cells included in the cell counts was based on average nuclear (not soma) diameter of 4-6 ~.m. In this way, inclusion of nonneuronal cells and double counting of neurons were effectively eliminated. All cell counts were done blind as to the treatment conditions of the embryos being examined. Statistical significance was determined using unpaired Student's t test with Bonferroni correction for multiple t tests.
Construction of IGF-I and IGF-II Plasmids with Oligonucleotide Inserts
For construction of a plasmid that allows production of exogenous "standard" IGF-I mRNA, the clGF-I cDNA (pGEM3Z; gift of Dr. Kajimoto and Rotwein, 1989) was subcloned into pBluescript (pKS-; Stratagene, Heidelberg, Germany). The cDNA was cut at position 550 with Saul, and a 53 bp oligonucleotide was inserted. For construction of IGF-II plasmids containing an insertion in the region to be amplified, a clGF-II cDNA plasmid (pBS SK+; gift of Dr. Brickell, UCL, London) was used. After deletion of the Sacll restriction site in the polylinker region, Deal was used to cut the cDNA at position 342, and a 57 bp oligonucleotide was inserted. The correct insertion of both oligonucleotides was confirmed by sequencing. The standards were prepared using T3 RNA polymerase, and concentrations were determined spectrophotometrically. PCR Total cellular RNA was prepared from E7 sympathetic ganglia and from immunoselected cells according to Chomczynski and Sacchi (1987) . The selected cells were pelleted and directly lysed in the guanidinium isothiocyanate solution. Defined amounts of an exogenous IGF-I or IGF-II mRNA standard were added to the tissue samples before RNA extraction. The amount of exogenous standard to be added to the samples was determined empirically for each tissue so that exogenous and endogenous RNA were present in amounts represented in the standard curve and in roughly equivalent amounts. After reverse transcription and amplification of both endogenous and exogenous IGF mRNAs using identical PCR primers, two products were obtained, a larger standard and a smaller band, resulting from the amplification of endogenous IGF mRNA. The products were identified by hybridization with a specific internal oligonucleotide probe. By the parallel amplification of defined amounts of standard IGF-I or IGF-II mRNA, the levels of endogenous IGF mRNAs could be determined. Tissues negative for PCR products after 27 cycles were re-analyzed in the absence of exogenous standard at 40 cycles.
IGF.I
Endogenous IGF-I and exogenous standard mRNA for IGF-I were reverse transcribed and amplified using the same pair of primers. The upstream primer 1 (GCTGAGCTGGTTGATGCTCTT) corresponds to positions 412-432 of mature IGF-I, and the 3' primer 2 (ACCTCTACAT-GACACGAGGTTATTT) corresponds to positions 560-584 (Kajimoto and Rotwein, 1989) . The region amplified encloses an intron-exon border . The amplification results in 226 and 173 bp cDNA fragments for the standard and endogenous IGF-I cDNA, respectively. No amplification product was observed with genomic DNA or IGF-II cDNA or in the absence of IGF-I mRNA. Total RNA was used for cDNA synthesis by AMV reverse transcriptase (10 U; Life Sciences, St. Petersburg, Florida) using primer 2 of the PCR. First-strand synthesis was carried out at 42°C for 60 min in 50 Ill using the First Strand Synthesis Kit (Stratagene), and 10 i 11 of the single strand cDNA reaction mixture was used for the PCR reaction containing the following components: 5 ILl of 10 x TaqBuffer (1 x TaqBuffer is 10 mM Tris-HCI [pH 8.3], 50 mM KCI, 1.5 mM MgCI2, 0.001% gelatine), 2 p_l of dNTPs (each 5 mM), primer 1 and primer 2 (each 600 ng), 0.5 p.I (5 U/I~I) of TaqPol (AmpliTaq polymerase from Perkin-Elmer; 0berlingen, Germany), and water to a final volume of 50 p,l. PCR reaction was started by"hot start" (94°C; 1 min), carried out (27 cycles) in a Perkin-Elmer temperature cycler at 94°C for 1 min, 62°C for 1.5 min, and 72°C for 1.5 min each cycle, and terminated with 5 rain at 72°C.
For quantitation, different amounts of IGF-I cDNA were amplified in parallel. Aliquots of the PCR products were applied to a 2.3% agarose gel containing ethidium bromide. Following electrophoresis the DNA was blotted to nylon membrane (Hybond N+; Amersham), and the blots were hybridized with an internal 32P-labeled clGF-I oligonucleotide probe (positions 490-513 of IGF-I cDNA; 5-8 x 108 cpm/ml; 9 x 108 cpm/p,g). After autoradiography the film was densitometrically scanned, and the values for endogenous mRNA were corrected according to the recovery of the exogenous standard. The levels of IGF-I and IGF-II mRNA are expressed as femtograms of mRNA per microgram of total RNA.
IGF-II
For reverse transcription and PCR of endogenous IGF-il and exogenous standard mRNA for IGF-II, the same pair of primers was used. The 21 bp upstream primer 1 (AGACCAGTGGGGACGAAATAAC) corresponds to positions 310-330 of mature IGF-II, and the 26 bp 3'primer 2 (GGACGCACGGGCAGCCATGGCCACCG) corresponds to positions 633-658 (Taylor et al., 1991; Taylor and Brickell, unpublished data) . The region amplified encloses an intron-exon border. The amplification results in a 405 bp product for the standard and a 348 bp product for endogenous IGF-II. The reverse transcription was performed as described for IGF-I, and for PCR the same components were used. PCR reactions were started by "hot start," carried out (27 cycles) at 94°C, 65°C, and 72°C for 1 rain each cycle, and terminated with 5 min at 72°C. No product was obtained without template and with IGF-I cDNA. For hybridization, an internal 32P-labeled clGF-II oligonucleotide probe corresponding to positions 415-438 of the mature peptide was used. Conditions for hybridization and washing procedures were identical to those used for IGF-I blots.
